gdc
FDA Approvals, News & UpdatesGynecologic CancersNewsworthyOvarian Cancer

Lynparza Approved as Maintenance Treatment for Ovarian Cancer

In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
December 2017 Vol 3 No 6

Also on August 17, 2017, the FDA approved Lynparza (olaparib; from AstraZeneca) tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a complete or partial response to platinum-based chemotherapy.

On the same day, the FDA also approved a tablet form of Lynparza for patients with deleterious or suspected deleterious germline BRCA mutation–positive advanced ovarian cancer who have received 3 or more previous chemotherapies.

The most common side effects with Lynparza include anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, constipation, stomatitis, headache, dysgeusia, dyspepsia, decreased appetite, arthralgia, or myalgia.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep Approved for the Treatment of Relapsed or Refractory Multiple Myeloma
Adrug called Blenrep (belantamab mafodotin-blmf) was recently approved by the Food and Drug Administration (FDA) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies (including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent).
FDA Approvals, News & UpdatesLeukemia
Imbruvica/Rituximab Combo Approved for First-Line Leukemia
The Food and Drug Administration (FDA) has expanded the use of the anticancer drug Imbruvica (ibrutinib) to be used in combination with rituximab for the treatment of the most common type of leukemia in adults, chronic lymphocytic leukemia (CLL), or its variant called small lymphocytic lymphoma (SLL).
Last modified: June 20, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country